MATERNAL AND EARLY CHILD HEALTH |
![]() |
Date of Completion: 23.6.97 |
The contents of this bulletin are likely to be valid for approximately one year, by which time significantly new research evidence may become available
(Users are advised to consult the supporting evidence for a consideration of all the implications of a recommendation)
| 14.1 In PREGNANCY | |
| The Statements | The Evidence |
| 14.1a. Smoking cessation programmes,
in particular behavioural strategies, can be effective for a small minority of smokers in
increasing mean birthweight. Poorly structured advice may lead to some smokers spending
their pregnancy in a state of guilt and inadequacy. There are no trials of pre-pregnancy
intervention to determine if such advice reduces the prevalence of smoking or, more
importantly, improves outcomes(i,ii). (Health gain notation - 4 "unknown". The efficacy of smoking prevention programmes in general will be covered in the Healthy Living Bulletin - due for publication in 1998) |
i. Dolan-Mullen P, Ramirez G, Groff JY. A
meta-analysis of randomized trials of prenatal smoking cessation interventions. American
Journal of Obstetrics and Gynecology. 1994; 171(5): 1328-1334. (Type
I evidence - meta-analysis); ii. Chalmers I, Enkin M, Keirse MJNC. Effective care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 244-247, 251 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. pp. 22-23) |
| 14.1b. Excessive
alcohol consumption in pregnancy is associated with increased morbidity and mortality
in the fetus. While no trials of cessation programmes exist, guidelines on management are
available (i). (Health gain notation - 5 "potential for harm") |
i. Royal College of Obstetricians and
Gynaecologists. Alcohol consumption in pregnancy RCOG Guidelines No. 9. London: RCOG, 1996 (Type V evidence - expert opinion) |
| 14.1c. There is no
evidence to recommend nutrient therapy by dietary interventions and
supplementation in suspected fetal growth impairment(i)i. (Health gain notation - 5 "unlikely to be beneficial") |
i. Gulmezoglu AM,
Hofmeyr GJ. Nutrient treatment for suspected impaired fetal growth. Cochrane database
of systematic reviews. Cochrane Library 1997 Issue 1. (Type I evidence - systematic review of small trials with methodological limitations) |
| 14.1d. There is evidence of the
value of an accurate early ultrasonic dating of all pregnancies in avoiding
unnecessary induction for suspected poor growth (i,ii). (Health gain notation - 2 "likely to be beneficial") |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 424-426 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. p. 41); ii. Managing post-term pregnancy. Drug and Therapeutics Bulletin 1997; 35(3): 17-18 (Type V evidence - expert opinion) |
| 14.1e. In prediction of poor
growth, measurement of fundal height has shown quite good specificity and
sensitivity (i). (Health gain notation - 2 "likely to be beneficial") |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 p. 415 (Type IV evidence - observational studies. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. p. 62) |
| 14.1f. Fetal movement counting
has been widely used as a test of fetal compromise. The two randomised controlled trials
available provided no evidence of reduction in intrauterine death (i). (Health gain notation - 3 "trade-off between beneficial and adverse effects) caveat: Its widespread use does result in more hospital attendances, induction and elective deliveries. Limiting to selected at risk cases may be better practice. |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 440-452 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. p. 62) |
| 14.1g. There is
no evidence that routine screening by repeat biophysical profiles or Doppler
studies identifies affected pregnancies(i,ii). (Health gain notation - 5 "unlikely to be beneficial") |
i. Neilson JP,
Alfirevic Z. Doppler ultrasound in high risk pregnancies. Cochrane database of
systematic reviews. Cochrane Library. 1997 Issue 4. (Type I evidence
- systematic review); ii. Alfirevic Z, Neilson JP. Biophysical profiles for fetal assessment in high risk pregnancies. Cochrane database of systematic reviews. Cochrane Library. 1997 Issue 1. (Type I evidence - systematic review) |
| 14.1h. There is evidence that selective
ultrasound is effective in identifying at-risk pregnancies but there is a need for
prospective studies to identify optimum techniques(i). (Health gain notation 21 "likely to be beneficial") |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 420-436 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. pp. 63-70) |
| 14.1i. There is evidence that Doppler
studies, to monitor the high risk infant, are effective to determine the optimum
timing of delivery (i). (Health gain notation -1 "beneficial") |
i. Neilson JP, Alfirevic Z. Doppler ultrasound in high risk pregnancies. Cochrane database of systematic reviews. Cochrane Library. 1997 Issue 4. (Type I evidence - systematic review) |
| 14.1j. There is
no evidence that biophysical profiles to monitor the high risk infant are effective
in improving outcome(i)i. (Health gain notation - 5 "unlikely to be beneficial") |
i. Alfirevic Z, Neilson JP. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane database of systematic reviews. Cochrane Library. 1997 Issue 4. (Type I evidence - systematic review) |
| 14.1k. The value
of hospitalization and bed rest for suspected fetal compromise have not been
substantiated(i). (Health gain notation - 5 "unlikely to be beneficial") |
i. Gulmezoglu AM, Hofmeyr GJ. Hospitalisation for bedrest for suspected impaired fetal growth. Cochrane database of systematic reviews. Cochrane Library 1997 Issue 4. (Type II evidence - randomised controlled trial) |
| 14.1l. External
cardiotocography may be effective in identifying deteriorating fetal condition (in
at-risk pregnancies) following suddent reduction of fetal movement or ante-partum
haemorrhage(i). (Health gain notation - 2 "likely to be beneficial") caveat: Because of the difficulties in interpretation, its widespread use is not recommended |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 479-492 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. pp. 66-67) |
| 14.1m. Preliminary and limited
trial evidence gives initial support to the value of maternal oxygen therapy but
this should only be used in the context of well-designed trials(i). (Health gain notation - 3 "trade-off between beneficial and adverse effects") |
i. Gulmezoglu AM,
Hofmeyr GJ. Maternal oxygen therapy in suspected impaired fetal growth. Cochrane
database of systematic reviews. Cochrane Library 1997 Issue 4. (Type I evidence - systematic review of two trials) |
| 14.1n. There is inadequate
evidence at present to support the routine use of calcium channel blockers in
pregnancy where the risk of impaired fetal growth is increased, but further trials are
indicated (i). (Health gain notation - 4 "unknown") |
i. Gulmezoglu AM,
Hofmeyr GJ. Calcium channel blockers in suspected impaired fetal growth. Cochrane
database of systematic reviews. Cochrane Library 1997 Issue 4. (Type II evidence - randomised controlled trial) |
| 14.1o. Plasma volume expansion
for impaired fetal growth is theoretically promising but further research is needed (i). (Health gain notation - 4 "unknown") |
i. Gulmezoglu AM,
Hofmeyr GJ. Plasma volume expansion for suspected impaired fetal growth. Cochrane
database of systematic reviews. Cochrane Library 1997 Issue 4. (Type V evidence - expert opinion; The two randomised controlled trials reviewed were both excluded because of methodological shortcomings) |
| 14.2 IN LABOUR | |
| The Statements | The Evidence |
| 14.2a. There is no dispute
regarding the value of fetal surveillance to identify distress in labour.
Auscultation of the fetal heart during, and immediately following, contractions has been
conventionally used to identify changes indicative of imminent hypoxia (i). (Health gain notation - 1 "beneficial") |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 846-882 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. pp. 208-209); |
| 14.2b. The passage of thick meconium is associated with an increased risk of fetal and neonatal mortality (thick meconium at onset of labour carries a 5-7 times increased risk of perinatal death)(i). | i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 847-848 (Type IV evidence - observational studies. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. p. 208) |
| 14.2c. Electronic fetal heart
monitoring by electocardiography provides the most reliable method of monitoring the
fetal heart in labour by identification of changes in base rate, decelerations and loss of
baseline variability(i). (Health gain notation - 3 "trade-off between beneficial and adverse effects") caveat: Continuous electronic monitoring, while reassuring for many women creates anxiety for others, and limits activity in labour (see statement o). |
i. Chalmers I, Enkin M, Keirse MJNC. Effective
care in pregnancy and childbirth. Oxford: Oxford University Press, 1989 pp. 846-878 (Type I evidence - systematic review. Summary in Enkin M, Keirse MJNC, Renfrew M, Neilson J. A guide to effective care in pregnancy and childbirth. 2nd ed. Oxford: Oxford University Press. 1995. pp. 210-214) |
| 14.2d. The use of continuous
electronic monitoring versus auscultation, especially without the capacity to
measure fetal pH increases the use of Caesarean section (relative risk = 1.33) and
operative vaginal deliveries (relative risk = 1.23)(i). (Health gain notation - 3 "trade-off between beneficial and adverse effects") caveat: The increase in Caesarean section is not associated with a reduction in mortality (provided there is equal emphasis on recognition and action in the presence of fetal heart abnormality) although a decrease in Apgar scores of <4 at 1 minute and neonatal seizures has been demonstrated(ii). |
i. McDonald D, Grant A, Sheridan-Pereira M,
Boylan P, Chalmers I. The Dublin randomised controlled trial of intrapartum fetal heart
rate monitoring. American Journal of Obstetrics and Gynecology. 1985; 152(5):
524-539 (Type II evidence - randomised controlled trial of 12,964 women); ii. Thacker SB, Stroup DF, Peterson HB. Continuous electronic fetal heart monitoring during labour. Cochrane Database of Systematic Reviews. Cochrane Library. 1997 Issue 4. (Type I evidence - systematic review) |
| 14.2e. Current consensus is to
limit continuous electronic fetal heart monitoring to high risk cases, including those
with interventions (induction, agumentation or epidural analgesia), and use either
intermittent auscultation or electronic monitoring for those with neither signs nor risk
of compromise. Further trials are needed for both low and high risk groups(i,ii,iii). (Health gain notation - 3 "trade-off between beneficial and adverse effects") |
i. Thacker SB,
Stroup DF, Peterson HB. Continuous electronic fetal heart monitoring during labour.
Cochrane Database of Systematic Reviews. Cochrane Library. 1997 Issue 4. (Type I evidence - systematic review); ii. Spencer JAD, Ward RHT, (eds.). Intrapartum fetal surveillance. Recommendations arising from the 26th RCOG Study Group. London: Royal College of Obstetricians and Gynaecologists, 1993 (Type V evidence - expert opinion) iii. MIDIRS. Fetal heart rate monitoring. Leaflet No. 2 MIDIRS, January 1996 (Type V evidence - expert opinion) |
Health Evidence Bulletins: Wales, Duthie Library, UWCM, Cardiff CF14 4XN. e-mail: weightmanal@cardiff.ac.uk